X4 Pharmaceuticals (XFOR) Prepaid Assets (2017 - 2026)
X4 Pharmaceuticals' (XFOR) quarterly Prepaid Assets came in at $3.3 million in Q2 2026, down 32.67% on a YoY basis from $5.0 million in Q2 2025, and up 32.84% quarter-over-quarter from $2.5 million in Q1 2026.
Analysis
X4 Pharmaceuticals (XFOR) Prepaid Assets (2017 - 2026) Analysis & Trends
X4 Pharmaceuticals (XFOR) has reported Prepaid Assets for 10 consecutive years, with $3.3 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Prepaid Assets fell 32.67% year-over-year to $3.3 million; the trailing twelve-month figure through Jun 2026 stood at $3.3 million (down 32.67% YoY), and the FY2025 full-year result was $3.5 million, down 36.88% from the prior year.
- Prepaid Assets rose to $3.3 million in Q2 2026 per XFOR's latest filing, from $2.5 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $7.3 million in Q4 2023 and bottomed at $2.5 million in Q1 2026.
- Historically, Prepaid Assets has averaged $4.8 million across 5 years, with a median of $4.9 million in 2022.
- The sharpest annual moves came in 2024 and 2026: Prepaid Assets soared 38.58% in 2024, then plunged 43.97% in 2026.
- Over 5 years, Prepaid Assets stood at $5.8 million in 2022, then advanced by 25.68% to $7.3 million in 2023, then retreated by 23.43% to $5.6 million in 2024, then slumped by 36.88% to $3.5 million in 2025, then declined by 5.39% to $3.3 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $3.3 million, $2.5 million, and $3.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn |
| 10 | X4 Pharmaceuticals | 510.43 Mn | 315.33 Mn | 7.19 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.34 Mn |
| Mar 31, 2026 | 2.51 Mn |
| Dec 31, 2025 | 3.53 Mn |
| Sep 30, 2025 | 4.93 Mn |
| Jun 30, 2025 | 4.96 Mn |
| Mar 31, 2025 | 4.48 Mn |
| Dec 31, 2024 | 5.59 Mn |
| Sep 30, 2024 | 4.48 Mn |
| Jun 30, 2024 | 4.98 Mn |
| Mar 31, 2024 | 5.76 Mn |
| Dec 31, 2023 | 7.30 Mn |
| Sep 30, 2023 | 5.80 Mn |
| Jun 30, 2023 | 5.52 Mn |
| Mar 31, 2023 | 4.16 Mn |
| Dec 31, 2022 | 5.81 Mn |
| Sep 30, 2022 | 4.95 Mn |
| Jun 30, 2022 | 4.36 Mn |
| Mar 31, 2022 | 3.59 Mn |
| Dec 31, 2021 | 5.34 Mn |
| Sep 30, 2021 | 3.66 Mn |